A Phase 2 interventional study of Etrasimod and Etrasimod in Alopecia Areata, sponsored by Pfizer. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-26.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 5th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Etrasimod
Drug: Etrasimod
Drug: Placebo
Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Percent change from baseline in SALT I is reported in terms of Least square mean and standard error.
Time frame: DB Treatment Period: Baseline (before dose on Day 1), Week 24
Change From Baseline in SALT I at Week 24: DB Treatment Period
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Change from baseline in SALT I is reported in terms of Least square mean and standard error.
Time frame: DBT Period: Baseline, Week 24
Percentage of Participants Who Achieved Greater Than or Equal to (>=) 30%, >= 50% and >=75% Improvement From Baseline in SALT I at Week 24: DB Treatment Period
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for alopecia areata (AA). Investigator determine the percent scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total percent scalp hair loss with a maximum score of 100. Score range from 0 to 100, where 0 =no scalp hair loss to 100 = complete scalp hair loss, higher scores indicated more scalp hair loss. Percentage of participants who achieved \>=30%, \>=50%, \>=75% improvement from baseline in SALT I at Week 24 was reported in this outcome measure.
Time frame: DB Treatment Period: Baseline, Week 24
Number of Participants With Adverse Events (AE): DB Treatment Period
An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of progressive multifocal leukoencephalopathy (PML). AEs included serious AEs and all non-SAEs.
Time frame: DB Treatment Period: From first dosing date in DB up to (before the first dosing date in OLE) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks)
Number of Participants With Adverse Events: OLE Period
An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of PML. AEs included serious AEs and all non-SAEs.
Time frame: OLE period: From first dosing date in OLE up to last dosing date + 4 weeks + 3 days (maximum up to 33 weeks)
The study consisted of a double-blind (DB) treatment period (24 weeks) followed by an open label extension (OLE) period (28 weeks). A total of 80 participants with moderate-to-severe alopecia areata (AA) were enrolled in the DB treatment period of the study. Out of 80 participants, 65 participants entered in the subsequent OLE period.
| Milestone | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] |
|---|---|---|---|---|---|---|---|---|
| Started | 31 | 25 | 24 | 0 | 0 | 0 | 0 | 0 |
| Treated | 31 | 25 | 23 | 0 | 0 | 0 | 0 | 0 |
| Completed | 24 | 24 | 17 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 1 | 7 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 24 | 20 | 13 |
| Treated | 0 | 0 | 0 | 4 | 4 | 24 | 20 | 13 |
| Completed | 0 | 0 | 0 | 2 | 1 | 21 | 19 | 9 |
| Not completed | 0 | 0 | 0 | 2 | 3 | 3 | 1 | 4 |
| Withdrew: Not reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 3 | 2 | 1 | 0 |
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Percent change from baseline in SALT I is reported in terms of Least square mean and standard error.
| Percent change of scalp surface area | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo |
|---|---|---|---|
| Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period | -13.79 ± 8.557 | -21.43 ± 6.926 | 0.35 ± 8.933 |
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Change from baseline in SALT I is reported in terms of Least square mean and standard error.
| % of scalp surface area | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo |
|---|---|---|---|
| Change From Baseline in SALT I at Week 24: DB Treatment Period | -8.87 ± 4.142 | -8.62 ± 3.351 | 0.36 ± 4.314 |
SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for alopecia areata (AA). Investigator determine the percent scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total percent scalp hair loss with a maximum score of 100. Score range from 0 to 100, where 0 =no scalp hair loss to 100 = complete scalp hair loss, higher scores indicated more scalp hair loss. Percentage of participants who achieved \>=30%, \>=50%, \>=75% improvement from baseline in SALT I at Week 24 was reported in this outcome measure.
| Percentage of participants | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DBT Period: Placebo |
|---|---|---|---|
| >= 30% Improvement | 23.5 (6.81 to 49.90) | 36.0 (17.97 to 57.48) | 12.5 (1.55 to 38.35) |
| >= 50% Improvement | 11.8 (1.46 to 36.44) | 28.0 (12.07 to 49.39) | 12.5 (1.55 to 38.35) |
| >= 75% Improvement | 5.9 (0.15 to 28.69) | 12.0 (2.55 to 31.22) | 0.000 (0.00 to 20.59) |
An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of progressive multifocal leukoencephalopathy (PML). AEs included serious AEs and all non-SAEs.
| Participants | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo |
|---|---|---|---|
| Number of Participants With Adverse Events (AE): DB Treatment Period | 21 | 20 | 18 |
An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of PML. AEs included serious AEs and all non-SAEs.
| Participants | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DBT] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events: OLE Period | 3 | 2 | 18 | 14 | 11 |
Collected over From first dosing date up to last dosing date + 4 weeks + 3 days (maximum up to 57 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Treatment Period: Etrasimod 2 mg | 0/31 (0%) | 0/31 (0%) | 11/31 (35.5%) |
| DB Treatment Period: Etrasimod 3 mg | 0/25 (0%) | 0/25 (0%) | 12/25 (48%) |
| DB Treatment Period: Placebo | 0/23 (0%) | 0/23 (0%) | 11/23 (47.8%) |
| OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | 0/24 (0%) | 1/24 (4.2%) | 14/24 (58.3%) |
| OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | 0/20 (0%) | 0/20 (0%) | 11/20 (55%) |
| OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Event | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] |
|---|---|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/31 | 0/25 | 0/23 | 1/4 | 0/4 | 0/24 | 0/20 | 0/13 |
| MyelopathyNervous system disorders | 0/31 | 0/25 | 0/23 | 0/4 | 0/4 | 1/24 | 0/20 | 0/13 |
| RadiculopathyNervous system disorders | 0/31 | 0/25 | 0/23 | 0/4 | 0/4 | 1/24 | 0/20 | 0/13 |
| Event | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/31 | 2/25 | 3/23 | 1/4 | 0/4 | 1/24 | 1/20 | 1/13 |
| DizzinessNervous system disorders | 0/31 | 2/25 | 1/23 | 0/4 | 1/4 | 0/24 | 1/20 | 0/13 |
| Atrioventricular block second degreeCardiac disorders | 0/31 | 0/25 | 0/23 | 0/4 | 1/4 | 0/24 | 0/20 | 0/13 |
| BradycardiaCardiac disorders | 0/31 | 0/25 | 0/23 | 0/4 | 1/4 | 0/24 | 0/20 | 0/13 |
| Abdominal pain upperGastrointestinal disorders | 0/31 | 0/25 | 0/23 | 1/4 | 0/4 | 0/24 | 0/20 | 0/13 |
| Gastrointestinal disorderGastrointestinal disorders | 0/31 | 0/25 | 0/23 | 1/4 | 0/4 | 0/24 | 0/20 | 0/13 |
| Limb injuryInjury, poisoning and procedural complications | 0/31 | 0/25 | 0/23 | 0/4 | 1/4 | 0/24 | 0/20 | 1/13 |
| Electrocardiogram abnormalInvestigations | 0/31 | 0/25 | 0/23 | 1/4 | 0/4 | 0/24 | 0/20 | 0/13 |
| HypopnoeaRespiratory, thoracic and mediastinal disorders | 0/31 | 0/25 | 0/23 | 0/4 | 1/4 | 0/24 | 0/20 | 0/13 |
| Upper respiratory tract infectionInfections and infestations | 1/31 | 1/25 | 3/23 | 0/4 | 0/4 | 2/24 | 2/20 | 3/13 |
DB Treatment Period randomized set included all randomized participants, irrespective of whether they received any study drug. OLE Safety set (SAF) included all participants who received at least 1 dose of study drug. Participants in DB treatment period and OLE period are not exclusive. Eligible participants from DB treatment period entered OLE period after completing treatment in DB treatment period.
| Age, Continuous(Years) | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] | Total |
|---|---|---|---|---|---|---|---|---|---|
| DB Treatment Period | 36.6 ± 12.60 | 41.7 ± 16.63 | 43.4 ± 13.25 | — | — | — | — | — | 40.4 ± 14.33 |
| OLE Period | — | — | — | 38.0 ± 14.99 | 43.5 ± 15.67 | 42.4 ± 16.65 | 35.1 ± 12.17 | 44.8 ± 11.53 | 40.4 ± 14.35 |
| Sex: Female, Male(Participants) | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] | Total |
|---|---|---|---|---|---|---|---|---|---|
| DB Treatment Period — Female | 16 | 21 | 22 | 0 | 0 | 0 | 0 | 0 | 59 |
| DB Treatment Period — Male | 15 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 21 |
| OLE Period — Female | 0 | 0 | 0 | 1 | 3 | 20 | 9 | 13 | 46 |
| OLE Period — Male | 0 | 0 | 0 | 3 | 1 | 4 | 11 | 0 | 19 |
| Ethnicity (NIH/OMB)(Participants) | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] | Total |
|---|---|---|---|---|---|---|---|---|---|
| DB Treatment Period — Hispanic or Latino | 4 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 10 |
| DB Treatment Period — Not Hispanic or Latino | 25 | 21 | 20 | 0 | 0 | 0 | 0 | 0 | 66 |
| DB Treatment Period — Unknown or Not Reported | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 4 |
| OLE Period — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 7 |
| OLE Period — Not Hispanic or Latino | 0 | 0 | 0 | 4 | 4 | 21 | 14 | 12 | 55 |
| OLE Period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | DB Treatment Period: Etrasimod 2 mg | DB Treatment Period: Etrasimod 3 mg | DB Treatment Period: Placebo | OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period] | OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period] | Total |
|---|---|---|---|---|---|---|---|---|---|
| DB Treatment Period — American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| DB Treatment Period — Asian | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| DB Treatment Period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| DB Treatment Period — Black or African American | 2 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 11 |
| DB Treatment Period — White | 25 | 16 | 17 | 0 | 0 | 0 | 0 | 0 | 58 |
| DB Treatment Period — More than one race | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| DB Treatment Period — Unknown or Not Reported | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| OLE Period — American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| OLE Period — Asian | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 4 |
| OLE Period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| OLE Period — Black or African American | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 4 | 10 |
| OLE Period — White | 0 | 0 | 0 | 2 | 2 | 15 | 16 | 9 | 44 |
| OLE Period — More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| OLE Period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2020 to primary completion in Jun 2023, 34 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 34 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod